Information Provided By: 
Fly News Breaks for December 3, 2018
XLRN
Dec 3, 2018 | 07:17 EDT
UBS analyst Carter Gould noted Acceleron presented Phase 3 data for luspatercept over the weekend, which he said yielded few surprises. The analyst said the concerns over the small thrombotic events in the BELIEVE trial were overblown, in his opinion, in the context of the unmet need. More importantly, the lack of any apparent follow-on signal in the MEDALIST trial likely puts the issue to rest, he believes. Gould reiterated his Buy rating and $62 price target on Acceleron shares
News For XLRN From the Last 2 Days
There are no results for your query XLRN
